Search Result

Results for "

Btk

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (247) ADC Payload (1) Akt (2) Antibiotic (1) Apoptosis (20) Arp2/3 Complex (1) Autophagy (1) Bcl-2 Family (1) Bcr-Abl (1) BCRP (1) BMX Kinase (5) ByeTAC (1) c-Kit (1) c-Met/HGFR (1) Calcium Channel (1) Caspase (2) CCR (1) CDK (1) CXCR (2) Cytochrome P450 (2) Dengue Virus (2) DNA/RNA Synthesis (1) Drug Intermediate (3) Drug Isomer (1) Drug Metabolite (2) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (6) EGFR (10) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (2) FAK (1) Fc Receptor (FcR) (1) Flavivirus (2) FLT3 (5) Fluorescent Dye (3) Fungal (1) Glutathione S-transferase (1) HMG Family (1) IKZF Family (2) Insulin Receptor (1) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (4) Itk (7) JAK (11) LAG-3 (2) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (16) MEK (1) MNK (1) Molecular Glues (2) mTOR (1) NF-κB (3) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (2) Parasite (1) PARP (1) PD-1/PD-L1 (2) PERK (1) PI3K (2) PIKfyve (1) Pim (1) Polo-like Kinase (PLK) (2) PROTAC Linkers (7) PROTAC-Linker Conjugates for PAC (1) PROTACs (35) Pyroptosis (1) RANKL/RANK (1) Reference Standards (15) RET (1) Small Interfering RNA (siRNA) (3) Src (8) STAT (1) Syk (3) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1) Tyrosinase (1)
By Research Areas:	Cancer (214) Cardiovascular Disease (4) Endocrinology (1) Infection (6) Inflammation/Immunology (93) Metabolic Disease (5) Neurological Disease (8)
Click Chemistry:	PROTAC Synthesis (2) Azide (1) Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

289

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Btk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153321

Bexobrutideg 1 Publications Verification NX-5948; Btk-IN-24	PROTACs Btk	Inflammation/Immunology Cancer
Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific *BTK* protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .

HY-160141

Catadegbrutinib BGB-16673; Btk-IN-29	PROTACs Btk NF-κB	Inflammation/Immunology Cancer
BGB-16673 (BGB-16673) is an orally active, selective *BTK* PROTAC degrader (IC₅₀=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .

HY-147943

*PROTAC BTK* Degrader-1**	PROTACs Btk	Cancer
PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC₅₀ value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth . PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-160167

Birelentinib DZD8586	Src Btk	Inflammation/Immunology Cancer
Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and *BTK* tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying *BTK* resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both *BTK*-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent *BTK* inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .

HY-122828

*PROTAC BTK* Degrader-2**	PROTACs Btk	Others
PROTAC BTK Degrader-2 is a potent BTK PROTAC degrader. PROTAC BTK Degrader-2 effectively reduces BTK protein levels .

HY-101941

BTK IN-1 SNS062 analog	Btk	Inflammation/Immunology Cancer
BTK IN-1 (SNS062 analog) is a potent *BTK* inhibitor, with an IC₅₀ of <100 nM.

HY-49421

BTK ligand 12	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 12 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). BTK ligand 12 can serve as an active control for the target protein ligand of NRX-0492 (HY-153357) .

HY-128403

BTK inhibitor 8	Btk	Inflammation/Immunology
BTK inhibitor 8 (Compound 27) is a *Btk* inhibitor with an IC₅₀ of 0.11 nM. BTK inhibitor 8 inhibits Btk activity. BTK inhibitor 8 suppresses B cell activation. BTK inhibitor 8 is applicable to research related to arthritis and asthma .

HY-163295

BTK degrader-1	ADC Payload Btk	Cancer
BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .

HY-101766

Btk inhibitor 2	Btk	Inflammation/Immunology
Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

HY-160966

*PROTAC BTK* Degrader-10**	PROTACs Btk	Cancer
PROTAC BTK Degrader-10 (Example 1P) is a PROTAC degrader for *BTK. PROTAC BTK* Degrader-10 can be used for research of chronic lymphocytic leukemia (CLL) (Pink: ligand for target protein (HY-170758); Black: linker (HY-W392857); Blue: ligand for E3 ligase Cereblon (HY-W733176))

HY-149391

*PROTAC BTK* Degrader-6**	PROTACs Btk	Inflammation/Immunology
PROTAC BTK Degrader-6 (Compound 15) is a PROTAC *BTK* degrader (DC₅₀: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6) .

HY-153536

*PROTAC BTK* Degrader-3**	PROTACs Btk	Cancer
PROTAC BTK Degrader-3 is a potent *BTK* degrader with a DC₅₀ value of 10.9 nM of BTK degradation in Mino cells. PROTAC BTK Degrader-3 has the potential for B-cell malignancies, including chronic lymphoid malignancies research .

HY-152212

BTK-IN-19	Btk	Inflammation/Immunology
BTK-IN-19 (Compound 51) is a reversible *BTK* inhibitor with an IC₅₀ of <0.001 μM .

HY-168302

BTK ligand 10	Ligands for Target Protein for PROTAC Tyrosinase Btk	Cancer
BTK ligand 10 is the ligand of *BTK. BTK* ligand 10 can be used to synthesize NX-2127 (HY-153220) .

HY-170413

*PROTAC BTK* Degrader-12**	PROTACs Btk	Cancer
PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based *BTK* degrader (Pink & black: BTK ligand & linker (HY-170414); Black: linker (HY-30105); Blue: CRBN ligand ( HY-W245311)) .

HY-130255

BTK inhibitor 13	Btk	Inflammation/Immunology
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM .

HY-176381

BTK ligand 11-alcohol-PEG6-azido	E3 Ligase Ligand-Linker Conjugates	Cancer
BTK ligand 11-alcohol-PEG6-azido is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as TDP-43 degrader-1 (HY-122828) .

HY-147580

BTK-IN-10	Btk	Cancer
BTK-IN-10 is a potent *BTK* inhibitor with IC₅₀s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111) .

HY-159947

*PROTAC BTK* Degrader-11**	PROTACs Btk	Cancer
PROTAC BTK Degrader-11 is a PROTAC degrader that can break down *BTK, with a DC₅₀* of 1.7 nM. PROTAC BTK Degrader-11 can be used in cancer research. (Pink: target protein ligand (HY-159956); Black: linker; Blue: E3 ligase (HY-150839)) .

HY-125997

BTK inhibitor 10	Btk	Inflammation/Immunology
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of *BTK. BTK* plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-179076

BTK/IKZF1/3 ligand 1	Ligands for Target Protein for PROTAC Btk IKZF Family	Cancer
BTK/IKZF1/3 ligand 1 is a BTK/IKZF1/3 PROTAC ligand. BTK/IKZF1/3 ligand 1 can be conjugated with E3 ligase Ligand (HY-41547) and linker to synthesize PROTAC BTK/IKZF1/3 Degrader-1 (HY-179077). PROTAC BTK/IKZF1/3 Degrader-1 can be used for cancer research .

HY-179077

*PROTAC BTK/IKZF1/3 Degrader-1*	PROTACs Btk IKZF Family	Cancer
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179076); Blue: CRBN ligand (HY-41547))

HY-170324

BTK-IN-40	Btk	Others
BTK-IN-40 (compound 375) is a *BTK* inhibitor .

HY-179562

BTK degrader-2	Btk	Cancer
BTK degrader-2 (Example 2) is a *BTK* dual-functional degrading agent, which causes the degradation of BTK through the ubiquitin-proteasome pathway. BTK degrader-2 can be used for the study of B-cell-related diseases .

HY-148832

BTK-IN-20	Btk	Inflammation/Immunology Cancer
BTK-IN-20 (compound 283) is a *BTK* tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .

HY-162280

*PROTAC BTK* Degrader-9**	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-131705

BTK inhibitor 17	Btk	Inflammation/Immunology
BTK inhibitor 17 is a potent and orally active irreversible *BTK* inhibitor with an IC₅₀ of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research .

HY-176526

BTK degrader-1 intermediate	Drug Intermediate Btk	Cancer
BTK degrader-1 intermediate (compound 5) is an intermediate for the synthesis of BTK degrader-1 (HY-163295). BTK degrader-1 can be used as an ADC toxin to synthesize antibody-drug conjugate (ADC) .

HY-139881

BTK inhibitor 19	Btk	Cancer
BTK inhibitor 19 is a highly selective, covalent *BTK* inhibitor (IC₅₀ = 2.7 nM).

HY-168963

*PROTAC BTK* Degrader-13**	PROTACs Btk Itk p38 MAPK	Inflammation/Immunology Cancer
PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for *BTK* with a DC₅₀ of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of *BTK* with an IC₅₀ of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC₅₀ of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting *Btk* can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-177103

Midobrutinib	Btk	Cancer
Midobrutinib (Example 13) is a *BTK* inhibitor (IC₅₀: 0.813 nM). Midobrutinib can be used for research of diseases involving BTK, particularly cancer .

HY-155072

*PROTAC BTK* Degrader-5**	PROTACs Btk	Cancer
PROTAC BTK degraders-5(compound 3e) is a selective *BTK* PROTAC degrader with a DC₅₀ value of 7.0 nM in JeKo-1 cells. PROTAC BTK degraders-5 has no off-target effect on degrading CRBN neosubstates. PROTAC BTK degraders-5 has anti-proliferation effect on various lymphoma tumor cells and can be used in chronic lymphoid malignancies research (Blue: E3 ligand (HY-W440230), Black: linker HY-168297；Pink:BKT inhibitor (HY-150898)) ¹.

HY-152201

BTK-IN-18	Btk	Cancer
BTK-IN-18 is a potent, reversible *BTK* inhibitor with an IC₅₀ of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo .

HY-147582

BTK-IN-12	Btk	Cancer
BTK-IN-12 is a potent *BTK* inhibitor with IC₅₀s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8) .

HY-158064

BTK-IN-36	Btk	Cancer
BTK-IN-36 (S-016) is a *BTK* inhibitor, with IC₅₀ of 0.5 nM. BTK-IN-36 can be used in cancer-related research .

HY-141689

BTK-IN-3	Btk	Cancer
BTK-IN-3 (example 1) is an inhibitor of *BTK. BTK*-IN-3 can used to study cancer .

HY-175543

BTK ligand 16	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 16 is a *BTK* ligand that can be used for synthesis of TQ-3959 (HY-175541) .

HY-169307

BTK-IN-38	Btk	Cancer
BTK-IN-38 (Example 125) is a potent *BTK* inhibitor. BTK-IN-38 inhibits DOHH2 and BT474 cells proliferation with IC₅₀s of 114 and 340 nM, respectively .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of *BTK. BTK-IN-32 activates full-length BTK* and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-143718

*JAK3/BTK-IN-3*	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143717

*JAK3/BTK-IN-2*	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

*JAK3/BTK-IN-5*	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, example 35)

HY-143719

*JAK3/BTK-IN-4*	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-143716

*JAK3/BTK-IN-1*	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002) .

HY-176172

BTK-IN-44	Btk	Cancer
BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .

HY-162257

BTK-IN-34	Btk	Cancer
BTK-IN-34 (compound 9h) is a selective *BTK* inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

Cat. No.	Product Name

HY-L129

Target Protein Ligand Library

94 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 94 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L156

Autoimmune Disease Compound Library

943 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 943 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

HY-L009

Kinase Inhibitor Library

3,849 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,849 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L009M

Kinase Inhibitor Library Mini

271 compounds

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 271 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent *BTK, JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6744

Chaetoglobosin A	Infection Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Marine natural products Endogenous metabolite Marine microorganism Disease Research Fields Indole Alkaloids Source Classification	Apoptosis Endogenous Metabolite Fungal Parasite Arp2/3 Complex
Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia .

HY-110013

Terreic acid	Microorganisms Source Classification	Btk Antibiotic
Terreic acid, a quinone epoxide antibiotic, acts as an effective *Btk* inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM .

Recombinant Proteins Recommended:

Brutons Tyrosine Kinase (BTK)

Species:	Human (19)
Tag:	His (6) Strep (3) Tag Free (1) Avi (7) GST (2)
Source:	sf9 insect cells (11) Sf9 insect cells (8)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702730

	BTK Protein, Human (Active, Biotinylated, C481S, sf9, His, Avi) Btk; Bruton agammaglobulinemia tyrosine kinase; tyrosine-protein kinase Btk;	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, Biotinylated, C481S, sf9, His, Avi) is the recombinant human-derived BTK, expressed by Sf9 insect cells, with His, Avi labeled tag.

HY-P704026

	BTK Protein, Human (Active, C481S, sf9, GST,) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, C481S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704025

	BTK Protein, Human (Active, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704027

	BTK Protein, Human (Active, M437R, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, M437R) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704028

	BTK Protein, Human (Active, T316A, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, T316A) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704029

	BTK Protein, Human (Active, T474I, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, T474I) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704030

	BTK Protein, Human (Active, T474S, sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, GST, T474S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P705642

	BTK Protein, Human (Active, sf9, C-His) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Active, sf9, C-His) is the recombinant human-derived BTK protein, expressed by sf9 insect cells , with C-His labeled tag.

HY-P705742

	BTK Protein, Human (Active, sf9) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705744

	BTK Protein, Human (Active, Biotinylated, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705741

	BTK Protein, Human (Biotinylated, L528W, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705743

	BTK Protein, Human (Active, R28H, sf9, His-GST) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705745

	BTK Protein, Human (Active, P190K, sf9, His-StrepII) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705746

	BTK Protein, Human (Active, C481R, sf9, His-StrepII) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705747

	BTK Protein, Human (Active, Y485F, sf9, His-StrepII) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705748

	BTK Protein, Human (Active, Biotinylated, C481R, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705749

	BTK Protein, Human (Active, Biotinylated, V416L, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705750

	BTK Protein, Human (Active, Biotinylated, M437R, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

HY-P705751

	BTK Protein, Human (Active, Biotinylated, T474I, sf9, Avi) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17600S

Acalabrutinib-d4
Acalabrutinib-d₄ (ACP-196-d₄) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor . Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10997S

Ibrutinib-d5
Ibrutinib-d₅ (PCI-32765-d₅) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor .

HY-100659S

Dihydrodiol-Ibrutinib-d5
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards *BTK* approximately 15 times lower than that of ibrutinib .

HY-101474S

Zanubrutinib-d5
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor .

HY-101474BS

(R)-Zanubrutinib-d5
(R)-Zanubrutinib-d₅ is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-160219S

BTK-IN-33
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-135334S

ACP-5862-d4

ACP-5862-d₄ is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC₅₀ of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC₅₀ of 3 nM and EC₅₀ of 8 nM .

Host:	Mouse (4) Rabbit (4)
Reactivity:	Human (8) Monkey (2)
Application:	IHC-P (5) ICC/IF (5) IP (4) IHC-F (2) WB (8) ELISA (3)
Isotype:	IgG (4) IgG1 (4)
Conjugation:	Non-conjugated (8) Biotin (7)
Clonality:	Monoclonal (4) Monoclonal Antibody (1) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84493

	BTK Antibody (YA4190) Btk	WB, IHC-P, ICC/IF, ELISA	Human, Monkey
	BTK Antibody (YA4190) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BTK.

HY-P84493A

	BTK Antibody (YA4190)(PBS only) Btk	WB, IHC-P, ICC/IF, ELISA	Human, Monkey
	BTK Antibody (YA4190) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BTK.

HY-P86215

	BTK Antibody (YA5907) Btk; AGMX1; ATK; BPK; Tyrosine-protein kinase Btk; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IHC-P, ICC/IF, IP, ELISA	Human
	BTK Antibody (YA5907) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BTK.

HY-P80454

	*Phospho-BTK(Y223) Antibody (YA221)* Btk(Y223); Btk (phospho Y223); p-Btk (phospho Y223); Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton’s Tyrosine Kinase; Btk; Btk_HUMAN; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; XLA.	WB, IP	Human
	Phospho-BTK(Y223) Antibody (YA221) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-BTK(Y223).

HY-P80576

	BTK Antibody (YA816) Btk; AGMX1; ATK; BPK; Tyrosine-protein kinase Btk; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IP	Human
	BTK Antibody (YA816) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BTK.

HY-P80576A

	BTK Antibody (YA816)(PBS only) Btk; AGMX1; ATK; BPK; Tyrosine-protein kinase Btk; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IP	Human
	BTK Antibody (YA816) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BTK.

HY-P83523

	General Transcription Factor II I Antibody (YA3268) GTF2I; BAP135; WBSCR6; General transcription factor II-I; GTFII-I; TFII-I; Bruton tyrosine kinase-associated protein 135; BAP-135; Btk-associated protein 135; SRF-Phox1-interacting protein; SPIN; Williams-Beuren syndrome chromosomal region	WB, IHC-F, IHC-P, ICC/IF	Human
	General Transcription Factor II I Antibody (YA3268) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to General Transcription Factor II I.

HY-P83523A

	General Transcription Factor II I Antibody (YA3268)(PBS only) GTF2I; BAP135; WBSCR6; General transcription factor II-I; GTFII-I; TFII-I; Bruton tyrosine kinase-associated protein 135; BAP-135; Btk-associated protein 135; SRF-Phox1-interacting protein; SPIN; Williams-Beuren syndrome chromosomal region	WB, IHC-F, IHC-P, ICC/IF	Human
	General Transcription Factor II I Antibody (YA3268) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to General Transcription Factor II I.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-147943

*PROTAC BTK* Degrader-1**		PROTAC Synthesis
PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC₅₀ value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth . PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15809

(Rac)-Ibrutinib alkyne		Alkynes
(Rac)-Ibrutinib alkyne (Compound 8) is a *Btk* inhibitor with an IC₅₀ of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC₅₀ of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis .

HY-130504

Propargyl-PEG1-acid 1 Publications Verification		PROTAC Synthesis Alkynes
Propargyl-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-CRBN PROTACs Ibrutinib(HY-10997)-based PROTAC 4 and PROTAC 5. PROTAC 5 causes the degradation of BTK and induces the degradation of CSK, LYN, and LAT2 at 10 μM . Propargyl-PEG1-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159589

BTK-IN-37		Azide
BTK-IN-37 (compound 8d) is a *BTK* inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with K_i and IC₅₀ of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks